

15 October 2024

## **NOT RATED**

**HCL TECHNOLOGIES** 

IT Services

## Modest beat. Guidance broadly maintained

- Broad-based and better-than-expected growth. Guidance is broadly left unchanged. HCLT does not want to extrapolate strong 2Q into 2H
- Order inflow is the only weak spot, in our view. Believe Verizon likely contributed a large part of the incremental FY25 revenue
- 2Q performance is unlikely to push up consensus EPS much. Stock unrated currently. Will be initiating coverage soon

Girish Pai research@bobcaps.in

**Revenue growth better than HCLT's own expectation:** 1.6% constant currency (CC) QoQ (2.4% US\$ QoQ) was a tad better than our 1.2% estimate. HCLT stated that it was better than its own expectation by US\$ 22mn (~65bps) as it witnessed broad-based strength. There was a 90bps negative impact due to State Street JV divestment QoQ.

**Margin a tad better too:** EBIT margin at 18.6% was better than our estimate of 18.3%. Of the 149bps increase QoQ, 54bps came from better performance of HCLT Software. The services margin increased by 110bps QoQ driven by operating efficiencies.

**Broad-based growth:** BFSI growth would have been 4% QoQ had it not been for the State Street divestment. Called out European Auto and Aerospace in general to be areas of worry. Indicated that discretionary spending was a tad better than in 1QFY25.

**Guidance increased marginally:** HCLT raised its FY25 revenue growth guidance to 3.5-5% from 3-5% due to the better performance in 2Q. This implies 0.7-2.6% CQGR growth for the next two quarters. It held on to its 18-19% EBIT margin guidance.

**Cautious in extrapolating 2Q strength into 2H:** Sounded cautious due to issues around macro, geopolitics and elections in the US. Indicated existence of client-specific issues in automotive and aerospace sub verticals.

**TCV is a bit disappointing:** Just as in the case of TCS, we were a bit disappointed by the TCV (all net new) of US\$ 2.23bn as HCLT too had indicated that deals were pushed back from 1QFY25.

**Large client impact:** Just as the BSNL deal has likely driven growth for TCS in FY25, similarly we believe the Verizon deal has likely contributed to 60% of incremental revenue in FY25 for HCLT.

BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda Important disclosures and analyst certifications are provided at the end of the report.

Ticker/Price	HCLT IN/Rs 1,856
Market cap	US\$ 59.9bn
Free float	39%
3M ADV	US\$ 57.2mn
52wk high/low	Rs 1,866/Rs 1,209
Promoter/FPI/DII	61%/18%/16%
Source: NSE   Price as of 14 Oct 20	24

#### Stock performance



Source: NSE



HCL Software did well. Looks like some of the 3Q demand was brought forward. Despite a very strong performance in 2Q (9.4% YoY growth in CC terms), HCLT insisted that HCL Software would grow only in the mid-single digits in FY25.

Strong wins in GenAI-related programmes. Most of the deals are now getting embedded with AI capabilities. The company's GenAI platform AI force is now getting widely adopted for service transformation.

Management highlighted that 2Q growth was driven by two factors: the ramp-up of deals signed in the past two to three quarters, which includes a balance of efficiency-led deals, and significant opportunities in data, application modernisation and SAP. This mix of discretionary and non-discretionary growth provides confidence going forward.

Management indicated that the manufacturing segment, particularly automotive in Europe, is facing headwinds due to significant cost reductions and programme cancellations among large clients, a trend that began in 2Q. However, strong growth in the SAP business is partially offsetting these challenges.

Management stated that the wage hike (beginning on 1 October) will impact margins by 65 to 80 bps in 3Q, with an additional effect of 50 to 60 bps expected in 4Q.

HCLT noted a slight decline in headcount despite strong growth, explaining that the wage bill has increased. HCLT highlighted ongoing shifts in the workforce pyramid towards more specialised skills. Future hiring will focus on higher-end skills, with the wage bill expected to increase in line with growth. Even in fresher hiring it indicated a preference for specialised skills.

HCLT outlined assumptions for achieving the upper end of the 0-2% guidance for the services business, including expectations of similar furloughs as FY24 and the successful execution of signed deals, with some remaining from the previous quarter. It noted a strong pipeline, close to all-time highs, and anticipated good bookings for the remainder of the year.

HCLT has not assumed any contribution from the HPE Communication Technology Group (CTG) in the guidance. HCLT thinks that the revenue will be added in 3QFY25.





## Fig 1 – Quarterly results: Comparison of actuals with estimates

Y/E March (Rs bn)	2QFY24	1QFY25	2QFY25	YoY (%)	QoQ (%)	2QFY25E	Dev (%)
Net sales (US\$ mn)	3,225	3,364	3,445	6.8	2.4	3,430	0.5
Net sales	267	281	289	8.2	2.9	287	0.4
Employee costs	170	184	188	10.4	2.3	186	1.1
Gross margin % of sales	36.2	34.5	34.9			35.3	
SG&A	37	39	37	(0.3)	(5.0)	39	(5.0)
% of sales	13.9	13.9	12.8			13.6	
Depreciation and amortisation	10	10	10	(0.3)	0.9	10	1.1
% of sales	3.8	3.6	3.5			3.5	
EBIT	49.3	48.0	53.6	8.7	11.8	52.6	1.9
EBIT Margin (%)	18.5	17.1	18.6			18.3	
Other Income	2	8	3	54.1	(61.3)	3	15.0
Forex gain/(loss)	-0	1	0			0	
PBT	51	57	57	10.9	(0.4)	56	2.2
Provision for tax	13	14	15	12.0	0.1	14	2.7
Effective tax rate	25.3	25.4	25.5			25.4	
Minority share in profit / loss	0	0	0			0	
One-time bonus and DTL for Goodwill	0	0	0			0	
PAT (Reported)	38.3	42.6	42.4	10.5	(0.5)	41.5	2.0
NPM (%)	14.4	15.2	14.7			14.4	




### Fig 2 – US\$ revenue growth (YoY)






# Fig 3 – US\$ revenue growth (QoQ)




#### Fig 4 – QoQ CC revenue growth



### Fig 5 – Overall revenue growth YoY CC









Source: Company, BOBCAPS Research

## Fig 7 – ERDS growth YoY CC






#### Fig 8 – Products and Platforms growth YoY CC



Source: Company, BOBCAPS Research

#### Fig 9 - BFSI growth YoY CC - impacted by the State street divestment.




Source: Company, BOBCAPS Research


## Fig 10 – Manufacturing growth YoY CC







#### Fig 11 – Lifesciences and Healthcare growth YoY CC








Source: Company, BOBCAPS Research




#### Fig 13 – Quarterly net new TCV wins (US\$ bn)



#### Fig 14 – Gross margin and EBIT margin




## Fig 15 – SG&A spending



Source: Company, BOBCAPS Research


#### Fig 16 – Attrition trends





#### Fig 17 – OCF/ net income trend

Fig 18 – Quarterly snapshot



#### 2QFY23 3QFY23 4QFY23 1QFY24 2QFY24 3QFY24 4QFY24 1QFY25 2QFY25 Year to 31 Mar (Rs mn) 1QFY23 INR/US\$ 77.62 79.98 82.34 82.30 82.17 82.72 83.28 83.10 83.40 83.79 US\$ revenue (US\$ mn) 3,025 3,082 3,244 3,235 3,200 3,225 3,415 3,430 3,364 3,445 **INR** revenue 2,34,640 2,46,860 2,67,000 2,66,060 2,62,960 2,66,720 2,84,460 2,84,990 2,80,570 2,88,620 Gross margin 83,980 88,380 99,800 97,170 93,600 96,590 1,04,480 99,720 96,930 1,00,730 EBITDA 49,750 54,260 63,650 58,630 53,870 59,440 67,580 61,110 57,940 63,690 EBIT 39,920 44,280 49,340 52,290 48,360 44,600 50,180 47,960 53,620 56.150 Other income 3,450 1,570 2,360 1,940 2,590 3,250 1,440 3,570 2,510 9,120 PBT 43,370 45,850 53,730 51,930 46,960 51,280 58,740 52,690 57,080 56,870 10,960 12,950 Tax 10,560 12,760 12,120 11,650 15,230 12,740 14,480 14,500 PAT 34,900 39,830 32,830 40,970 35,340 38,320 43,500 39,860 42,580 42,350 EPS 12.1 12.9 15.1 14.7 13.0 14.1 16.0 14.7 15.7 15.6 YoY growth (%) US\$ revenue 11.2 10.4 9.0 5.8 4.6 5.3 6.0 5.1 6.8 8.1 **INR** revenue 16.9 19.5 19.6 17.7 12.1 8.0 6.5 6.7 8.2 7.1 6.7 4.7 Gross profit 11.9 17.0 17.0 11.5 93 2.6 3.6 4.3 EBITDA 1.4 12.2 18.0 16.0 8.3 9.5 6.2 4.2 7.6 7.2 EBIT 1.6 13.1 22.8 18.8 11.7 11.4 7.4 3.8 7.5 8.7 2.1 6.9 19.0 10.9 9.8 20.5 10.5 Net profit 7.6 6.2 0.1 QoQ growth (%) 1.1 1.9 5.3 0.8 5.9 US\$ revenue (0.3) (1.1)0.4 (1.9) 2.4 3.8 **INR** revenue 5.2 8.2 (0.4)(1.2)1.4 6.7 0.2 (1.6) 2.9 EBITDA (1.5) 9.1 17.3 (8.1) 10.3 13.7 9.9 (7.9)(9.6) (5.2)(10.6) EBIT (1.9) 10.9 18.1 (7.5)(7.8) 10.6 13.8 (4.4)11.8 (8.6) 6.3 17.4 (11.3) 8.4 13.5 6.8 (0.5) Net profit (2.8)(8.4) Margins (%) Gross margin 35.8 35.8 37.4 36.5 35.6 36.2 36.7 35.0 34.5 34.9 EBITDA 21.2 22.0 23.8 20.5 23.8 20.7 22.0 22.3 21.4 22.1 EBIT 17.0 17.9 19.6 18.2 17.0 18.5 19.7 17.6 17.1 18.6 PAT 14.0 14.1 15.3 15.0 13.4 14.4 15.3 14.0 15.2 14.7 14.6 13.5 14.5 15.1 13.5 13.9 12.8 SGA 13.8 13.9 13.0



## Fig 19 – Key metrics

Key Metrics	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
P&L (Rs mn)										
Revenue	2,34,640	2,46,860	2,67,000	2,66,060	2,62,960	2,66,720	2,84,460	2,84,990	2,80,570	2,88,620
EBITDA	49,750	54,260	63,650	58,630	53,870	59,440	67,580	61,110	57,940	63,690
PAT	32,830	34,900	40,970	39,830	35,340	38,320	43,500	39,860	42,580	42,350
Vertical mix (%)										
Banking, FS & Insurance (BFSI)	21.1	20.6	19.9	21.2	22.6	22.6	21.7	21.6	21.0	20.5
Hi-tech - Manufacturing	18.3	19.2	19.7	19.0	19.9	19.3	20.1	20.4	19.4	19.5
Telecom	9.2	9.2	9.4	8.8	7.6	8.0	9.7	11.5	12.2	12.1
Retail & CPG	9.4	9.2	8.9	9.0	9.1	9.6	9.6	9.1	9.4	9.6
Life Sciences	16.4	16.5	17.1	17.5	17.5	17.5	16.4	16.3	15.9	16.0
Energy-Utilities-Public Sector	10.2	10.2	10.2	10.2	10.0	9.9	9.7	8.8	9.1	9.2
Technology and Services	15.4	15.1	14.8	14.4	13.4	13.1	12.8	12.3	13.0	13.1
Geographical mix (%)										
US	64.2	64.8	63.5	63.8	64.5	64.5	64.5	65.2	66.0	65.1
Europe	27.8	27.5	29.1	28.9	28.7	28.5	29.0	28.9	27.9	28.4
Asia Pacific	8.0	7.7	7.4	7.3	6.8	7.0	6.4	5.9	6.1	6.5
Employees	2,10,966	2,19,325	2,22,270	2,25,944	2,23,438	2,21,139	2,24,756	2,27,481	2,19,401	2,18,621
Net new addition	2,089	8,359	2,945	3,674	(2,506)	(2,299)	3,617	2,725	(8,080)	(780)
Attrition (%)	23.8	23.8	21.7	19.5	16.3	14.2	12.8	12.4	12.8	12.9
Segmental revenue mix										
IT and Business Services	72.8	73.7	71.6	73.7	74.7	74.6	71.7	74.4	74.5	74.6
Engineering and R&D Services	16.6	17	16.6	16.1	15.4	16	16.4	16.1	15.9	15.8
Products & Platforms	11	9.8	12.3	10.6	10.4	9.9	12.3	10	9.9	9.9
Inter Segment	(0.4)	(0.5)	(0.5)	(0.4)	(0.5)	(0.5)	(0.4)	(0.5)	(0.3)	(0.3)



### Fig 20 – YoY and QoQ performance on various parameters

	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
QoQ growth (%)										
Geography wise										
US	3.3	2.8	3.1	0.2	0.0	0.8	5.9	1.5	(0.7)	1.0
Europe	(0.7)	0.8	11.4	(1.0)	(1.8)	0.1	7.8	0.1	(5.3)	4.3
Asia Pacific	(9.2)	(1.9)	1.2	(1.6)	(7.8)	3.7	(3.2)	(7.4)	1.4	9.1
Total	1.1	1.9	5.3	(0.3)	(1.1)	0.8	5.8	0.5	(1.9)	2.4
Non-US	(2.7)	0.2	9.1	(1.1)	(3.0)	0.8	5.6	(1.3)	(4.2)	5.1
Vertical wise										
Banking, FS & Insurance (BFSI)	2.0	(0.5)	1.7	6.2	5.5	0.8	1.7	(0.0)	(4.7)	(0.0)
Hi-tech - Manufacturing	2.7	6.9	8.0	(3.8)	3.6	(2.3)	10.3	1.9	(6.7)	2.9
Telecom	8.1	1.9	7.5	(6.7)	(14.6)	6.1	28.4	19.1	4.0	1.6
Retail	1.1	(0.3)	1.8	0.8	0.0	6.3	5.9	(4.8)	1.3	4.6
Life Sciences	11.2	2.5	9.1	2.0	(1.1)	0.8	(0.8)	(0.2)	(4.3)	3.1
Energy-Utilities-Public Sector	(3.7)	1.9	5.3	(0.3)	(3.0)	(0.2)	3.8	(8.9)	1.4	3.5
Technology & Services	(11.1)	(0.1)	3.2	(3.0)	(7.9)	(1.5)	3.5	(3.5)	3.7	3.2
Client concentration										
Top 5 clients	(2.4)	(2.7)	1.3	(2.2)	(4.0)	0.8	5.9	0.4	14.1	8.7
Top 10 clients	(1.0)	(1.3)	1.9	(3.0)	(3.9)	0.8	9.0	0.4	8.6	5.0
Top 20 clients	0.4	0.8	3.8	(1.7)	(3.2)	1.1	8.6	0.4	5.4	4.8
Segment wise										
IT and Business Services	0.2	3.2	2.3	2.6	0.3	0.6	1.8	4.2	(1.8)	2.6
Engineering and R&D Services	2.5	4.3	2.8	(3.3)	(5.4)	4.7	8.5	(1.4)	(3.1)	1.8
Products & Platforms	3.3	(9.2)	32.1	(14.1)	(2.9)	(4.1)	31.6	(18.3)	(2.9)	2.4
YoY growth (%)										
Geography wise										
US	13.2	14.0	9.8	9.8	6.3	4.1	6.9	8.4	7.6	7.8
Europe	10.8	7.3	12.0	10.4	9.2	8.4	4.9	6.0	2.2	6.5
Asia Pacific	(1.1)	(4.4)	(7.3)	(11.4)	(10.1)	(4.9)	(9.0)	(14.3)	(5.7)	(0.8)
Total	11.2	10.4	9.0	8.1	5.8	4.6	5.2	6.0	5.1	6.8
Non-US	7.9	4.5	7.5	5.2	4.9	5.5	2.1	1.9	0.7	5.0
Vertical wise										
Banking, FS & Insurance (BFSI)	6.2	6.8	2.8	9.6	13.3	14.8	14.8	8.0	(2.3)	(3.1)
Hi-tech - Manufacturing	18.3	18.5	22.6	14.1	15.0	5.2	7.4	13.9	2.5	7.9
Telecom	29.5	28.6	26.4	10.6	(12.6)	(9.0)	8.6	38.6	68.7	61.6
Retail	4.6	3.7	(4.0)	3.5	2.4	9.2	13.6	7.2	8.6	6.8
Life Sciences	24.1	19.1	29.4	26.9	12.9	11.0	1.0	(1.2)	(4.5)	(2.3)
Energy-Utilities-Public Sector	5.0	6.3	6.9	3.0	3.7	1.5	0.1	(8.5)	(4.3)	(0.7)
Technology & Services	(1.0)	(3.0)	(12.4)	(11.1)	(8.0)	(9.2)	(9.0)	(9.4)	2.0	6.8
Client concentration	,	. ,	( )	. ,	. ,	. ,	,	. ,		
Top 5 clients	(4.2)	(7.0)	(8.0)	(5.9)	(7.4)	(4.2)	0.2	2.9	22.3	31.9
Top 10 clients	3.7	0.3	(2.3)	(3.4)	(6.2)	(4.3)	2.4	6.0	19.8	24.9
Top 20 clients	5.7	5.6	4.5	3.2	(0.4)	(0.1)	4.5	6.8	16.3	20.5
Segment wise					()	()				•
IT and Business Services	13.2	12.1	10.5	8.5	8.5	5.9	5.4	7.0	4.8	6.8
Engineering and R&D Services	20.5	19.6	13.8	6.3	(1.9)	(1.5)	4.0	6.0	8.5	5.5
Products & Platforms	(9.9)	(11.0)	(4.1)	6.4	0.0	5.7	5.3	0.0	0.1	6.8
Source: Company, BOBCAPS Research	(/	()	1/							



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704**, **B Wing**, **Parinee Crescenzo**, **G Block**, **BKC**, **Bandra East**, **Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: **www.barodaetrade.com** 

CIN: U65999MH1996GOI098009



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### **General disclaimers**

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.



The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.